• This international, multicenter, randomized, double-blind phase III study intends to recruit 680 patients who have received radical gastrectomy (R0 resection, D2 or more extended lymphadenectomy) with postoperative pathological stage II or III (AJCC Cancer Staging Manual, 8th Edition) gastric or EGJ adenocarcinoma to evaluate the efficacy and safety of JS001 combined with postoperative adjuvant chemotherapy versus placebo combined with postoperative adjuvant chemotherapy. (centerwatch.com)
  • Maintenance tegafur-plus-uracil after adjuvant concurrent chemoradiotherapy may improve outcome for resected oral cavity squamous cell carcinoma with extranodal extension. (bvsalud.org)
  • To evaluate whether tegafur - uracil maintenance (UFTm) following postoperation adjuvant cisplatin -based concurrent chemoradiotherapy (CCRT) may reduce distant metastasis in patients with resected oral cavity squamous cell carcinoma (OSCC) with pathologic extranodal extension (pENE+). (bvsalud.org)
  • PRODIGY: A Phase III Study of Neoadjuvant Docetaxel, Oxaliplatin, and S-1 Plus Surgery and Adjuvant S-1 Versus Surgery and Adjuvant S-1 for Resectable Advanced Gastric Cancer. (hemonc.org)
  • Methods: Patients who received adjuvant tegafur-uracil therapy after lobectomy between April 2009 and March 2019 were retrospectively analyzed. (nii.ac.jp)
  • Conclusions: Our study suggested that anatomical displacement of the esophagus after lobectomy may affect the discontinuation of oral adjuvant chemotherapy in patients with lung cancer. (nii.ac.jp)
  • Purpose: To compare long-term disease-free survival (DFS) between patients receiving tegafur/gimeracil/oteracil (S-1) or capecitabine plus oxaliplatin (CAPOX) adjuvant chemotherapy (AC) for gastric cancer (GC). (gnu.ac.kr)
  • Backgrounds: Preventing distant recurrence and achieving local control are important challenges in rectal cancer treatment, and use of adjuvant chemotherapy has been studied. (elsevierpure.com)
  • However, no phase III study comparing adjuvant chemotherapy regimens for rectal cancer has demonstrated superiority of a specific regimen. (elsevierpure.com)
  • We therefore conducted a phase III study to evaluate the superiority of S-1 to tegafur-uracil (UFT), a standard adjuvant chemotherapy regimen for curatively resected stage II/III rectal cancer in Japan, in the adjuvant setting for rectal cancer. (elsevierpure.com)
  • Oba K. Efficacy of adjuvant chemotherapy using tegafur-based regimen for curatively resected gastric cancer: Update of a meta-analysis. (u-tokyo.ac.jp)
  • Kobayashi M, Tsuburaya A, Nagata N, Miyashita Y, Oba K, Sakamoto J. A feasibility study of sequential paclitaxel and S-1 (PTX/S-1) chemotherapy as postoperative adjuvant chemotherapy for advanced gastric cancer. (u-tokyo.ac.jp)
  • Some studies suggested that adjuvant chemotherapy only be recommended for patients with positive lymph node (Earle and Maroun 1999 ), or not recommended because the benefit was small (Janunger et al. (springeropen.com)
  • A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Global Study of Rilvegostomig in Combination With Chemotherapy as Adjuvant Treatment After Resection of Biliary. (who.int)
  • It is a component of the combination drug tegafur/uracil. (wikipedia.org)
  • Tegafur/uracil Tegafur/gimeracil/oteracil El Sayed YM, Sadée W (September 1983). (wikipedia.org)
  • Purpose: The current study assessed the efficacy and safety of biweekly oxaliplatin combining oral tegafur-uracil/leucovorin in treating chemonaive patients with advanced gastric cancer. (tmu.edu.tw)
  • Oral tegafur-uracil and leucovorin was given at a dose of 300 mg/m2/day and 60 mg/day three times daily from day 1 to 21, respectively, followed by a 1-week rest. (tmu.edu.tw)
  • Conclusions: Biweekly, oxaliplatin combining oral tegafur-uracil/ leucovorin in treating patients with advanced gastric cancer showed acceptable activity and manageable toxicity. (tmu.edu.tw)
  • Phase II trials of the oral regimen, UFT (tegafur and uracil) plus leucovorin, have demonstrated that this combination has antitumor activity similar to intravenous regimens of fluorouracil (5-FU) plus leucovorin. (cancernetwork.com)
  • Maintenance treatment of Uracil and Tegafur (UFT) in responders following first-line fluorouracil-based chemotherapy in metastatic gastric cancer: a. (oncotarget.com)
  • The purpose of this phase II study was to evaluate the efficacy and safety of Uracil and Tegafur (UFT) maintenance in metastatic gastric cancer patients following the first-line fluorouracil-based chemotherapy. (oncotarget.com)
  • This study aimed to assess the postoperative esophageal displacement after lobectomy and to clarify its impact on the continuity of tegafur-uracil treatment. (nii.ac.jp)
  • The dihydropyrimidine dehydrogenase (DPD) enzyme is responsible for the detoxifying metabolism of fluoropyrimidines, a class of drugs that includes 5-fluorouracil, capecitabine, and tegafur. (wikipedia.org)
  • A total of 42 patients who were assigned to the gemcitabine poststudy treatment arm received fluorouracil, capecitabine, tegafur, or S-1. (cancernetwork.com)
  • However, further studies are needed to verify the validity of HAIC for resectable liver metastasis from gastric cancer. (biomedcentral.com)
  • 2010 ). In the study, more than 40 % of patients had stage I gastric cancer in either the D1 or D2 group. (springeropen.com)
  • S-1 [Tegafur/Oteracil/gimeracil] (Oral) BSA (body surface area)-based (40, 50, or 60 mg) BID for 4 weeks on 2 weeks off in 42-day cycles. (who.int)
  • The results of this study could lead to a change to oral therapy as the standard of care for metastatic colorectal cancer, providing the efficacy and toxicity of UFT/leucovorin are at least equivalent due to the ease of administration and patient preference for oral regimens. (cancernetwork.com)
  • The primary goal of this study was to compare the survival rates of patients with previously untreated metastatic colorectal carcinoma in response to conventional 5-FU/leucovorin therapy vs UFT/leucovorin. (cancernetwork.com)
  • Additional study objectives included evaluation and comparison of the qualitative and quantitative toxicity and reversibility of toxicity of the oral (UFT/leucovorin) and intravenous (IV) (5-FU/leucovorin) regimens. (cancernetwork.com)
  • Tegafur is a chemotherapeutic prodrug of 5-fluorouracil (5-FU) used in the treatment of cancers. (wikipedia.org)
  • Tegafur, a prodrug of 5-fluorouracil (5-FU), is an oral fluorouracil antitumor drug used for the management of adenocarcinomas. (cun.es)
  • This study aimed to identify the optimal treatment regimen for patients with MSSCC by retrospectively reviewing the outcomes of MSSCC patients, who were treated with neoadjuvant intra-arterial chemoradiotherapy (NACR) followed by surgery, as well as patients who received definitive intra-arterial chemoradiotherapy alone. (brieflands.com)
  • Patients in the current study received 2-h i.v. infusion of oxaliplatin at a dose of 100 mg/m 2 after diluting in 500 mL 5% dextrose/water (dexan premedication), and 5-HT3 antagonist biweekly. (tmu.edu.tw)
  • A study by Fogh et al of induction chemoradiotherapy followed by surgery, a strategy that is widely used in treating esophageal cancer, found that perioperative morbidity and mortality with this approach was not significantly different in patients aged 70 years or older compared with younger patients. (medscape.com)
  • According to several studies, use of concurrent chemoradiotherapy can improve the locoregional control and overall survival (OS) of patients with locally advanced head and neck carcinomas, compared to radiotherapy alone ( 3 - 5 ). (brieflands.com)
  • Nine patients who were treated with intravenous chemoradiotherapy or radiotherapy alone were excluded from the study due to impaired renal function or poor performance, according to the definition by the Eastern Cooperative Oncology Group (ECOG) ( 15 ). (brieflands.com)
  • In this study we have attempted to compare the efficacy, safety, and impact on quality of life of biomodulated 5-FU vs biomodulated UFT. (cancernetwork.com)
  • This study was aimed at comparing the efficacy and safety of gemcitabine plus S-1 (GS) vs. GnP as first-line chemotherapy for advanced PDAC. (cancerbiomed.org)
  • Patients with previously untreated metastatic colorectal cancer with evaluable or measurable disease and good performance status (Eastern Cooperative Oncology Group £ 2) are eligible for entry into this study. (cancernetwork.com)
  • Patients with recurrent or metastatic nasopharyngeal carcinoma who received first-line gemcitabine plus cisplatin had longer overall survival (OS) compared with fluorouracil plus cisplatin, according to the results of the phase 3 GEM20110714 study (NCT01528618) published in the Journal of Clinical Oncology . (cancernetwork.com)
  • The GEM20110714 study established the role of first-line [gemcitabine plus cisplatin] for patients with [recurrent or metastatic nasopharyngeal carcinoma]. (cancernetwork.com)
  • A five-country study of cancers in patients with T1DM has reported that T1DM was correlated with the risk of several common cancers. (frontiersin.org)
  • Previous cohort studies also reported an overall increased standardized mortality ratio for cancers among patients with T1DM compared with the general population ( 14 ). (frontiersin.org)
  • Previous large cohort studies conducted in the UK suggested that neither the risk of urinary bladder cancer nor mortality from urinary bladder cancer was increased in patients with T1DM or T2DM ( 11 , 16 ). (frontiersin.org)
  • In addition, cohort studies undertaken in the UK ( 11 , 18 ) and the USA ( 19 ) reported that no significantly increased all-cause cancer mortality was found in patients with T1DM when compared to the general population. (frontiersin.org)
  • In this study, we investigate the effects of the perioperative administration of flurbiprofen axetil on postoperative recurrence in patients with non-small cell lung cancer. (bmj.com)
  • 4 5 However, surgery alone may not be a sufficient treatment because an observational study of 11 663 surgically treated patients with NSCLC showed that the 5-year overall survival (OS) rate in all patients was 69.6%, while the rates in patients with clinical stage IA, IB, IIA and IIB were 82.0%, 66.1%, 54.5% and 46.1%, respectively. (bmj.com)
  • The present study determined the relationship between TFF expression and clinicopathological findings, as well as long-term outcome in CRC patients. (spandidos-publications.com)
  • In the present study, we evaluated the mRNA expression levels of TFF1, TFF2 and TFF3 in excised CRC specimens and assessed the correlation between TFF expression and the clinicopathological findings in CRC patients. (spandidos-publications.com)
  • A total of 154 consecutive patients with CRC who underwent surgical resection of the primary tumor between January 2005 and December 2007 at the Saga University Hospital were enrolled in the present study. (spandidos-publications.com)
  • A total of 103 patients were included in this study, 64 patients in UFTm and 39 patients in non-UFTm. (bvsalud.org)
  • This study aimed to evaluate the ability of intra-arterial CRT alone to increase the overall survival (OS) of patients with MSSCC. (brieflands.com)
  • Forty patients with histologically confirmed MSSCC, who were treated at Tokyo Medical University Hospital (Tokyo, Japan) between February 1999 and June 2015, were enrolled in this study. (brieflands.com)
  • Background: This study aimed to determine the relationship between the pre-operative metabolic tumor volume (MTV) and the disease-free survival (DFS) of patients with stage I non-small cell lung cancer (NSCLC) using F-18 2-fluoro-2-deoxy-D-glucose (FDG) positron-emission tomography-computed tomography (PET-CT) scanning. (iiarjournals.org)
  • Nine hundred Chinese Han were recruited for this study (461 gout patients and 439 gout-free individuals). (her2signaling.com)
  • While most studies currently predict five-year survival in breast cancer, some studies have focused on developing 1-year survival prediction models or Comprehensive Prognostic Index (CPI) for breast cancer patients with multiple comorbidities [ 8 ]. (biomedcentral.com)
  • The follow-up time of breast cancer data with diagnosis in 2019 in the SEER database is less than two years, this study also used 1-year survival as the study outcome, to establish a predictive model to identify people with better and worse prognosis, especially people with a poorer prognosis, and to assist physicians in taking the best interventional treatment for patients promptly. (biomedcentral.com)
  • Materials and Methods: This retrospective multicenter observational study enrolled 983 patients who underwent curative gastrectomy with consecutive AC with S-1 or CAPOX for stage II or III GC at 27 hospitals in Korea between February 2012 and December 2013. (gnu.ac.kr)
  • 2. Sakamoto K, Okabayashi K, Matsumoto S, Matsui S, Seishima R, Shigeta K, Kitagawa Y. Drainage pattern of the splenic flexure vein and its accompanying arteries using three-dimensional computed tomography angiography: a single-centre study of 600 patients. (keio-colorectalsurgery.com)
  • Therefore, further studies are needed to clarify this point in a large patient population comprising resistant patients as well. (biomedcentral.com)
  • Studies on levamisole have been done only in adult patients, and there is no specific information comparing use of levamisole in children with use in other age groups. (offshorerx.com)
  • The review was triggered by data from several studies showing a higher number of skin cancer cases including cases of squamous cell carcinoma in patients using Picato. (europa.eu)
  • 3 Although there have been no randomised controlled trials to compare surgery with radiation therapy or chemotherapy, observational studies have suggested that surgery is the most curative treatment for lung cancer. (bmj.com)
  • The major side effects of tegafur are similar to fluorouracil and include myelosuppression, central neurotoxicity and gastrointestinal toxicity (especially diarrhoea). (wikipedia.org)
  • Gastrointestinal toxicity is the dose-limiting side effect of tegafur. (wikipedia.org)
  • The study is nearing completion, with no toxicity issues requiring protocol modification. (cancernetwork.com)
  • JS001/placebo will be given for up to 17 cycles after surgery, until intolerable toxicity, disease recurrence, patient's withdrawal of consent, investigator's judgment that the patient needs to be withdrawn from the study treatment, or death, whichever comes first. (centerwatch.com)
  • This is the first study to evaluate the effect of the perioperative administration of non-steroidal anti-inflammatory drugs (NSAIDs) on postoperative recurrence in non-small cell lung cancer. (bmj.com)
  • The aim of this study was to evaluate the relationship between this SNP and gout pathogenesis. (her2signaling.com)
  • Certara's Simcyp Simulator is the most sophisticated platform for determining first-in-human dose selection, designing more efficient and effective clinical studies, evaluating and advancing new drug formulations, predicting drug-drug interactions (DDIs) and PK outcomes in numerous virtual clinical populations. (onenucleus.com)
  • Previous studies have suggested that several factors are associated with recurrence or reduced survival, such as carcinoembryonic antigen, epithelial growth factor receptor, and cytokeratin-19 fragment ( 3 , 4 ). (iiarjournals.org)
  • Ethics and dissemination The study protocol was approved by the Clinical Research Review Board of Saitama Medical University in September 2019 (No. 192002) and will be approved by each institutional review board of all participating institutions before patient enrolment. (bmj.com)
  • This study complies with the latest version of the Declaration of Helsinki, Clinical Trial Act and related notifications. (bmj.com)
  • There are few reports on studies that investigated the clinical significance of TFFs expression using excised primary CRC specimens ( 19 ). (spandidos-publications.com)
  • This review integrates most experimental studies and clinical trials of various oncolytic viruses (OVs) in the diagnosis and treatment of GC. (frontiersin.org)
  • Signals are generated from several sources such as spontaneous reports, clinical studies and the scientific literature. (europa.eu)
  • The authors developed a high-performance liquid chromatography (HPLC) assay for the determination of tissue or plasma tegafur and 5-FU concentration in a single step extraction and a single HPLC injection. (cun.es)
  • Safety follow-up: adverse events will be closely followed up and recorded, until 60 days after the last dose of treatment or the end of study follow-up (death, loss to follow-up, withdrawal of consent form and the end of study), whichever comes first. (centerwatch.com)
  • Beneficial effects of multi-disciplinary rehabilitation in postacute COVID-19: an observational cohort study. (nih.gov)
  • Methods and analysis This study is a multicentre, parallel group, open label, randomised controlled trial. (bmj.com)
  • The authors conclude that the method described here is ideally suited for the therapeutic monitoring of 5-FU and tegafur. (cun.es)
  • Hobbs clearly notes the difference between in vitro (experiments carried out in test tubes, Petri dishes, etc.) and in vivo studies (experiments carried out in living animals or people) and writes in his introduction, "If an in vitro study shows a plant extract to have activity, for instance a cancer-inhibiting effect, there is no certainty that the extract will be useful in treating or preventing human cancers. (namyco.org)
  • Many medicines have not been studied specifically in older people. (offshorerx.com)
  • This study aimed to identify lipid biomarkers that reflect the smoking status and the postoperative recurrence risk. (biomedcentral.com)
  • Crohn's Disease-Associated Anorectal Cancer Has a Poor Prognosis With High Local Recurrence: A Subanalysis of the Nationwide Japanese Study. (keio-colorectalsurgery.com)
  • This retrospective study was approved by the institutional review board (approval code: T2019-0262), and the requirement for written informed consent was waived. (brieflands.com)
  • Studies in women breastfeeding have demonstrated harmful infant effects. (mayoclinic.org)
  • There are no adequate studies in women for determining infant risk when using this medication during breastfeeding. (offshorerx.com)
  • Epidemiological studies suggest associations between diabetes mellitus and some cancers. (frontiersin.org)
  • Some early studies found no significant associations between T1DM and a range of site-specific cancers ( 15 ). (frontiersin.org)
  • Study Group for Inflammatory Bowel Disease Associated Intestinal Cancers by the Japanese Society for Cancer of the Colon and Rectum. (keio-colorectalsurgery.com)
  • In the current study, we assessed the cytotoxic effects of idarubicin-Z HER2 affibody conjugate on the positive-HER2 cancer cell lines. (iranpath.org)
  • Further, previous studies have suggested that diabetes is associated with increased risk of cancer mortality ( 5 , 6 ). (frontiersin.org)
  • Similarly, some studies found no significant association between the risk of breast cancer and T1DM in women ( 11 , 17 ). (frontiersin.org)
  • Recent studies suggest that TFFs are involved in the development and progression of various types of cancer, including breast, lung, prostate, stomach and colon cancer ( 6 - 15 ). (spandidos-publications.com)
  • In order to conclude on whether Picato increases the risk of skin cancer, the PRAC will now carry out a thorough review of all available data, including from ongoing studies. (europa.eu)
  • Appropriate studies have not been performed on the relationship of age to the effects of nicotine skin patches in the pediatric population. (mayoclinic.org)
  • The retention times of 5-FU and tegafur were 5 and 16.5 minutes, respectively, and the internal standard retention times were 11.5 and 17.5 minutes for 5-bromouracil (5-BU) and beta-hydroxyethyltheophylline, respectively. (cun.es)
  • Tegafur was used as an internal standard. (biomedcentral.com)
  • The assay had good recovery (96.5% +/- 9.45% and 97.5% +/- 7.89% for 5-FU in plasma and tissue, respectively, and 88.5% +/- 12.17% and 104.9% +/- 8.77% for tegafur in plasma and tissue, respectively). (cun.es)